US Biosimilar Portfolio Hits 10-Year Mark in Growth Mode
Since the US regulatory and litigation pathway for biosimilars was signed into law in March 2010, the FDA has approved 28 biosimilar products, including 16 drugs with indications for patients with cancer.
Continued ADC Development in NSCLC Necessitates Improved Knowledge of Mechanisms and Biomarker Optimization
Neoadjuvant vs Perioperative Immune Checkpoint Blockade in Resectable NSCLC: How Do We Choose?
EGFR TKI–Based Combinations May Revolutionize Frontline EGFR+ NSCLC Management
Dr Olazagasti on a Case-Based Discussion of ALK-Mutated NSCLC Treatment
2 Commerce Drive Cranbury, NJ 08512